> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves CutisPharma’s Oral Vancomycin
- URL: https://www.fdaweb.com/fda-approves-cutispharmas-oral-vancomycin/
- Published: 2018-01-29T12:00:00.000Z
- Updated: 2026-09-14T23:17:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140626

FDA has approved a CutisPharma NDA for Firvanq (vancomycin hydrochloride) oral solution for treating *Clostridium difficile*\-associated diarrhea and enterocolitis caused by *Staphylococcus aureus*, including methicillin-resistant strains. The company says that Firvanq will replace its FIRST-Vancomycin Unit-of-Use Compounding Kit, which has been available to pharmacists that need a convenient way to compound vancomycin oral liquid therapy. The product will be available in 25 mg/mL and 50 mg/mL strengths in 150 mL and 300 mL sizes.